Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. Oktober 2015 04:00 ET | Quelle: Pluri Inc.

Pluristem to Participate in Three European Life Sciences Conferences in November

HAIFA, Israel, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that Company...
13. Oktober 2015 04:57 ET | Quelle: Pluri Inc.

Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications

HAIFA, Israel, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced it has expanded...
12. Oktober 2015 07:00 ET | Quelle: Pluri Inc.

Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications

HAIFA, Israel, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced it has expanded...
07. Oktober 2015 10:15 ET | Quelle: Pluri Inc.

Pluristem CEO Zami Aberman Elected to Board of Directors of the Alliance for Regenerative Medicine

HAIFA, Israel, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that its...
21. September 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem and NIAID Met With U.S. FDA and Agreed on Development Plan for Initiation of Pivotal Study of PLX-R18 in the Treatment of Acute Radiation Syndrome

HAIFA, Israel, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Pluristem...
10. September 2015 04:31 ET | Quelle: Pluri Inc.

Pluristem Provides Corporate and Financial Highlights for Fiscal Year 2015

HAIFA, Israel, Sept. 10, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, reported yesterday financial...
09. September 2015 04:00 ET | Quelle: Pluri Inc.

Pluristem Completed Successful Meeting With the U.S. FDA in Preparation for Filing an IND for PLX-R18 to Treat Incomplete Hematopoietic Recovery After Bone Marrow Transplantation

HAIFA, Israel, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has...
06. September 2015 07:00 ET | Quelle: Pluri Inc.

Pluristem President Yaky Yanay Elected as Co-Chairman of Israel Advanced Technology Industries

HAIFA, Israel, Sept. 6, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced its President and...
17. August 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications

HAIFA, Israel, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the U.S....
12. August 2015 04:00 ET | Quelle: Pluri Inc.

Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in Clinical Trials

HAIFA, Israel, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that Japan's...

Vorherige Seite

Nächste Seite